Pressemitteilung BoxID: 521056 (aap Implantate AG)
  • aap Implantate AG
  • Lorenzweg 5
  • 12099 Berlin
  • Ansprechpartner
  • Marc Heydrich
  • +49 (30) 75019-134

aap preliminary report: strong H1 2012 growth (Sales: +33%)

Further increase of sales forecast for the financial year 2012 to EUR 35.5 million

(PresseBox) (Berlin, ) Preliminary figures indicate that aap Implantate AG (XETRA: AAQ.DE), a global medical device company focused on innovative trauma products and biomaterials for the orthopaedic market, achieved 33% sales growth in the first half of the financial year 2012 with sales of EUR 18.8 million (previous year: EUR 14.1 million). Compared with the previous year, sales in the second quarter of 2012 rose by 17% to EUR 8.9 million from EUR 7.6 million. The first-half year-over-year growth was driven by higher product sales (EUR +2.5 million) and a new exclusive license agreement (EUR +2.2 million) signed in March 2012. Based on the sales results for the first three months of 2012, the Company anticipates first half 2012 EBITDA growth to be more than 50% and first half 2012 EBIT growth to exceed 100% as compared to the first half of 2011. The EBITDA in the second quarter of 2012 will not develop in the same way as the sales because of non-recurring one time effects in the second quarter of 2011 amounting to EUR 0.4 million.

Based on the strong results for the first an second quarter of 2012, the Company is increasing its sales forecast to approximately EUR 35.5 million for the financial year 2012, a corresponding growth of 22%. For the EBITDA the management board expects an increase of more than 25% to approximately EUR 5.2 million for the financial year 2012.

On the basis of, among other things, the current order intake, the Management Board anticipates for the third-quarter 2012 sales of EUR 7.6 million to EUR 8.0 million, corresponding to sales growth of 10% to 16%. For the first nine months of 2012, the Company expects sales growth of 26% to 28%. For the first nine months of 2012, the Management Board expects year-on-year EBITDA and EBIT growth of more than 40% and 100%, respectively, as compared to the first nine months of 2011.

aap plans to publish its full Q2 2012 report on August 14, 2012.

This release contains forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

aap Implantate AG

aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit